Medical Cannabis Improved Quality of Life, Anxiety, and Sleep in ADHD Patients Over 12 Months ↗
UK registry data from 68 ADHD patients shows medical cannabis associated with improved quality of life, reduced anxiety, and better sleep over 12 months.
Browse more cannabis research, findings, methods, and limitations.
UK registry data from 68 ADHD patients shows medical cannabis associated with improved quality of life, reduced anxiety, and better sleep over 12 months.
Among 12,401 US high schoolers, concurrent e-cigarette and cannabis use was linked to elevated depression, suicidal ideation, and suicide attempts, especially in females.
Study of 6,879 bariatric patients finds marijuana use did not worsen surgical outcomes or weight loss, but users had higher rates of depression and other substance use.
Pilot study detected THC in 80% of breath samples after cannabis smoking, but 31-36% baseline detection rates highlight challenges for cannabis breathalyzer development.
Chemistry study shows CBD converts to THC and six other psychoactive compounds under acidic conditions, with implications for CBD product manufacturing safety.
Novel peripherally restricted MAGL inhibitor LEI-515 reduced pain and inflammation through CB2 receptors without brain side effects or dependence in mice.
Zebrafish study shows terpinolene and beta-caryophyllene reduce anxiety through CB2 (not CB1) receptors, providing experimental support for the cannabis entourage effect.
Genetic risk for schizophrenia predicts more paranoia, depression, and cognitive difficulties from cannabis, even without clinical psychosis (replicated in independent sample).
Pilot study shows the cannabis terpene beta-myrcene impaired speed control and divided attention on a driving simulator without any cannabinoids.
Review of 294 studies finds poor diet, sedentary behavior, cannabis, and tobacco are equally strongly associated with multiple mental disorders, suggesting shared underlying causes.
Cannabis legalization reduced possession arrest racial gaps in DC and LA, but new public consumption arrests emerged with significant racial disparities.
Genetic study of the hemp palm reveals unstable sexual expression and evolution toward XY sex determination, explaining its invasive success in European Alps.
73% of psychosis outpatients needed health promotion for BMI, smoking, or substance use, but 61% received no health-promoting care.
Study finds olive oil and Synderman bases offer best cannabinoid extraction (~70%) and stability for pharmacy-prepared topical cannabis formulations.
Swedish study finds the ADHD-cannabis link is largely explained by conduct problems, which themselves are driven by sensation-seeking traits.
Mendelian randomization with large GWAS data finds no causal link between cannabis use or cannabis use disorder and primary open-angle glaucoma.
First reported case of cannabinoid hyperemesis syndrome from prescription CBD in a child with epilepsy, resolving after CBD discontinuation without seizure worsening.
Geriatrics clinic survey found elderly cannabis users treating sleep problems prefer THC over CBD, use daily, and take it right before bed — often without clinician guidance.
Review highlights non-psychoactive cannabinoids as promising anti-cancer agents for ovarian cancer with excellent tolerability in preclinical studies.
Review explores the paradox that cannabis-using schizophrenia patients show better cognition than non-users, despite cannabis worsening psychotic symptoms.
Study of 1,625 high schoolers finds childhood trauma and suicide attempts interact to amplify drinking, but independently predict cannabis use.
Combined binge drinking and cannabis use among adults 65+ surged 450% from 2015-2019, driven by the Baby Boomer generation changing attitudes.
After Michigan legalization, 17.3% of 1,135 cannabis toxicity ER visits involved anxiety, with edible users and younger patients at higher risk.
Case report of CHS in a 25-year-old with type 1 diabetes highlights diagnostic challenges and the importance of considering cannabis as a cause of recurrent vomiting.
Spine surgery study: cannabis users needed lower opioid doses but were 5x more likely to develop opioid use disorder, suggesting addiction vulnerability.
Study of 160 infertile men finds cannabis significantly elevated FSH, with mild, non-significant effects on sperm count, testosterone, and LH.
Biomarker study of 925 pregnant individuals finds significant racial disparities in cannabis and tobacco exposure after California legalization.
Qualitative study of 15 women reveals pregnant cannabis users avoid discussing use with providers, relying instead on internet and peers for information.
Large study of 195,204 young surgical patients finds no reduction in prolonged opioid use associated with medical marijuana access.
Survey of 227 SCI patients finds 88% reported >30% pain reduction from cannabis and 83% substituted pain medications including opioids.
Clinical perspective explores the unique challenges of diagnosing and treating cannabinoid hyperemesis syndrome during pregnancy.
Validated detached leaf assay provides quick screening of cannabis varieties for Botrytis resistance and treatment product efficacy.
Only 30% of pregnant women completed CUD treatment, with criminal justice and healthcare provider referrals significantly improving completion rates.
Pilot survey of 47 older adults finds 76% value cannabis for treatment but only 23% were asked about it by their doctor, relying instead on internet sources.
Cannabis did not reduce pain directly in HIV patients but attenuated how much pain severity interfered with daily functioning.
Fourteen novel compounds activate unidentified cannabinoid-like receptors (not CB1 or CB2) with low-nanomolar potency, providing new research tools.
Open-label study of 44 adults with drug-resistant focal epilepsy found CBD reduced seizures 50%+ in 87%, with significant quality of life improvements and no severe side effects.
CANN-DIR is a free, 10-language web platform that screens cannabinoid drug interactions using FDA data, filling a gap for non-prescription CBD users.
Prenatal co-exposure to tobacco and cannabis may increase childhood obesity risk beyond either substance alone.
Review explores medicinal cannabis as a potential option for challenging behavior in intellectual disability, noting limited but promising theoretical pathways.
Blood cannabinoid metabolite ratios outperform THC alone as indicators of recent cannabis use, potentially improving impairment testing accuracy.
Chart review reveals high rates of substance use among psychiatric emergency patients, emphasizing the need for integrated dual-diagnosis care.
Canadian service providers report youth cannabis use has not declined post-legalization, raising concerns about whether policy objectives are being met.
Review explores how combined alcohol and cannabis exposure during pregnancy may produce unique developmental effects through overlapping neurobiological mechanisms.
Network analysis shows CUD symptoms connect differently in men and women, suggesting gender-specific treatment approaches may be more effective.
Attentional bias toward cannabis cues interacts with craving and cognitive control, with associations linked to use severity.
Social media analysis reveals active consumer interest in THC-O-acetate despite minimal safety research, highlighting gaps between market availability and scientific knowledge.
Consumers report delta-8-THC provides medical benefits similar to delta-9-THC but with milder psychoactive effects and fewer side effects.
Multicenter study finds CBD shows antiseizure effects across epilepsy subtypes beyond its three approved indications.
Daily diary study reveals temporal links between substance use (including cannabis) and somatic symptom changes in fibromyalgia patients.